More than 40 years have passed since the CDC reported the first cases of HIV in the United States. In that time, we’ve ...
Gilead has chosen a partner for lenacapavir in the race to develop new low-frequency treatments for HIV. | Gilead has chosen ...
Merck's two-drug HIV regimen doravirine/islatravir maintained viral suppression and matched Gilead's Biktarvy in Phase 3 ...
Leaders in HIV research highlighted the critical role of that research has played in advancing HIV science over the past 40 years. In a commentary in Nature Medicine, they explained how U.S.-funded ...
Abbvie (($ABBV)) announced an update on their ongoing clinical study. AbbVie recently updated its clinical study titled A ...
When diagnosed with HIV, the timing of treatment initiation can significantly impact long-term health outcomes and quality of life. Medical experts increasingly advocate for immediate treatment ...
Investor's Business Daily on MSN
Gilead Sciences Dives As HIV Drug Misses Bullish Buy-Side Expectations
Gilead stock slumped late Thursday on soft product sales and lighter-than-expected revenue from its newcomer HIV prevention ...
B/F/TAF shows lower ART switching rates and higher persistence among HIV patients, especially those with mental health or ...
The NIH funding will help address a "traditional barrier" to health care, says Elizabeth Evans, professor of community health ...
Addressing the question of whether and how immune cells (macrophages) in the central nervous system (CNS) traffic out, ...
More than 230 people became infected with HIV in Indiana, worsened by delayed action from former Gov. Mike Pence. Experts and ...
"You know, it's not the best news. But there was other news that could have been a lot worse, you know?" Charlie Sheen said.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback